iTeos Therapeutics (NASDAQ:ITOS) Lowered to “Neutral” Rating by JPMorgan Chase & Co.

JPMorgan Chase & Co. downgraded shares of iTeos Therapeutics (NASDAQ:ITOS) from an overweight rating to a neutral rating in a research note issued to investors on Tuesday, MarketBeat reports. JPMorgan Chase & Co. currently has $8.00 price objective on the stock, down from their prior price objective of $15.00.

Several other analysts have also weighed in on ITOS. Wedbush reiterated an “outperform” rating and set a $25.00 target price on shares of iTeos Therapeutics in a research report on Wednesday, March 5th. HC Wainwright reiterated a “buy” rating and set a $46.00 price target on shares of iTeos Therapeutics in a research report on Thursday, March 6th. Finally, Wells Fargo & Company lowered their target price on shares of iTeos Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a research note on Tuesday, April 29th.

iTeos Therapeutics Price Performance

NASDAQ ITOS opened at $7.85 on Tuesday. The firm has a market capitalization of $300.45 million, a price-to-earnings ratio of -2.49 and a beta of 1.39. The company’s fifty day moving average is $6.56 and its two-hundred day moving average is $7.43. iTeos Therapeutics has a 52-week low of $4.80 and a 52-week high of $18.70.

iTeos Therapeutics (NASDAQ:ITOS) last posted its quarterly earnings results on Monday, April 28th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.94) by $0.14. As a group, sell-side analysts expect that iTeos Therapeutics will post -3.49 earnings per share for the current fiscal year.

Institutional Trading of iTeos Therapeutics

A number of institutional investors have recently made changes to their positions in ITOS. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of iTeos Therapeutics in the fourth quarter valued at about $42,000. CWM LLC lifted its holdings in shares of iTeos Therapeutics by 428.7% in the first quarter. CWM LLC now owns 8,554 shares of the company’s stock worth $51,000 after acquiring an additional 6,936 shares during the last quarter. Virtus ETF Advisers LLC boosted its position in iTeos Therapeutics by 58.2% during the 4th quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company’s stock worth $69,000 after buying an additional 3,293 shares during the period. Forefront Analytics LLC acquired a new stake in iTeos Therapeutics during the 4th quarter worth approximately $85,000. Finally, Graham Capital Management L.P. bought a new position in iTeos Therapeutics during the 4th quarter worth approximately $85,000. Institutional investors own 97.16% of the company’s stock.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.